Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
2,387 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04385290 | Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)(MOSAIC) | recruiting | Phase 1 / Phase 2 | 214 | Technische Universität DresdenOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT04191616 | Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet(SELECT) | completed | Phase 2 | 54 | AmgenINDUSTRY | 8 | Sep 4, 2025 |
| clinicaltrials |
| NCT06912529 | Axicabtagene Ciloleucel CAR T-cells in Patients With Relapsed or Refractory Primary Mediastinal B-cell Lymphoma(PRIME-CAR) | terminated | Phase 2 | 1 | Universität MünsterOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT03525678 | A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody | completed | Phase 2 | 221 | GlaxoSmithKlineINDUSTRY | 8 | Sep 3, 2025 | clinicaltrials |
| NCT05323656 | A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) | completed | Phase 2 | 55 | Calliditas Therapeutics Suisse SAINDUSTRY | 7 | Sep 2, 2025 | clinicaltrials |
| NCT00777036 | A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib | completed | Phase 2 | 133 | Bristol-Myers SquibbINDUSTRY | 18 | Aug 29, 2025 | clinicaltrials |
| NCT05549505 | A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery | completed | Phase 2 | 152 | Arvinas Inc.INDUSTRY | 4 | Aug 29, 2025 | clinicaltrials |
| NCT06784791 | Preoperative Amivantamab or Amivantamab and Carboplatin/Pemetrexed Treatment in Patients With Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR)(NEOpredict-EGF) | recruiting | Phase 2 | 20 | University Hospital, EssenOTHER | 3 | Aug 29, 2025 | clinicaltrials |
| NCT03850574 | Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia(TUSCANY) | recruiting | Phase 1 / Phase 2 | 240 | Aptose Biosciences Inc.INDUSTRY | 6 | Aug 26, 2025 | clinicaltrials |
| NCT05578872 | A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1). | completed | Phase 1 / Phase 2 | 29 | Anaveon AGINDUSTRY | 5 | Aug 26, 2025 | clinicaltrials |
| NCT03769532 | MRD-guided Treatment in NPM1mut AML Patients(PEMAZA) | terminated | Phase 2 | 26 | Technische Universität DresdenOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT06679582 | Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML | terminated | Phase 1 / Phase 2 | 24 | Sutro Biopharma, Inc.INDUSTRY | 9 | Aug 24, 2025 | clinicaltrials |
| NCT03597295 | A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202) | completed | Phase 2 | 94 | Incyte CorporationINDUSTRY | 9 | Aug 21, 2025 | clinicaltrials |
| NCT05080790 | Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma(DiTuSarc) | completed | Phase 2 | 7 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT06082167 | Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma(STELLAR-305) | active not recruiting | Phase 2 / Phase 3 | 600 | ExelixisINDUSTRY | 26 | Aug 17, 2025 | clinicaltrials |
| NCT07124884 | 5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced Unresectab(COLOSOTO) | not yet recruiting | Phase 2 | 300 | Federation Francophone de Cancerologie DigestiveOTHER | 4 | Aug 15, 2025 | clinicaltrials |
| NCT02872714 | A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201) | completed | Phase 2 | 263 | Incyte CorporationINDUSTRY | 11 | Aug 14, 2025 | clinicaltrials |
| NCT02924376 | Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202) | completed | Phase 2 | 147 | Incyte CorporationINDUSTRY | 12 | Aug 14, 2025 | clinicaltrials |
| NCT03314181 | A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma | active not recruiting | Phase 2 | 156 | AbbVieINDUSTRY | 7 | Aug 14, 2025 | clinicaltrials |
| NCT04086264 | IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 218 | AbbVieINDUSTRY | 6 | Aug 14, 2025 | clinicaltrials |
| NCT01078662 | Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats | completed | Phase 2 | 298 | AstraZenecaINDUSTRY | 6 | Aug 13, 2025 | clinicaltrials |
| NCT05583071 | Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL(MTR²) | recruiting | Phase 2 | 20 | University of CologneOTHER | 1 | Aug 13, 2025 | clinicaltrials |
| NCT07120620 | PriCoTTF Study: TTFields Before and During Radiotherapy for Newly Diagnosed Glioblastoma(PriCoTTF) | completed | Phase 1 / Phase 2 | 33 | Sied KebirOTHER | 1 | Aug 13, 2025 | clinicaltrials |
| NCT04581824 | Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) | terminated | Phase 2 | 243 | GlaxoSmithKlineINDUSTRY | 12 | Aug 8, 2025 | clinicaltrials |
| NCT05690048 | Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA)(FLORA) | recruiting | Phase 2 | 48 | Michael DillOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT03599713 | A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201) | completed | Phase 2 | 107 | Incyte CorporationINDUSTRY | 12 | Aug 5, 2025 | clinicaltrials |
| NCT05253807 | Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration(FIGHT-210) | completed | Phase 2 | 8 | Incyte CorporationINDUSTRY | 5 | Aug 5, 2025 | clinicaltrials |
| NCT05480306 | Phase 2 Study of DKN-01 in Colorectal Cancer(DeFianCe) | completed | Phase 2 | 188 | Leap Therapeutics, Inc.INDUSTRY | 3 | Aug 3, 2025 | clinicaltrials |
| NCT03235245 | Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib(EBIN) | active not recruiting | Phase 2 | 271 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Aug 1, 2025 | clinicaltrials |
| NCT05980598 | TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma(BelieveIT-201) | terminated | Phase 2 | 27 | Ascendis Pharma A/SINDUSTRY | 8 | Aug 1, 2025 | clinicaltrials |
| NCT02205047 | Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma(INNOVATION) | completed | Phase 2 | 172 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 13 | Jul 31, 2025 | clinicaltrials |
| NCT03535740 | A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib(ALTA-2) | completed | Phase 2 | 103 | Ariad PharmaceuticalsINDUSTRY | 15 | Jul 31, 2025 | clinicaltrials |
| NCT05061134 | A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition(MONETTE) | active not recruiting | Phase 2 | 194 | AstraZenecaINDUSTRY | 11 | Jul 31, 2025 | clinicaltrials |
| NCT02730416 | Combination Chemotherapy With Nintedanib / Placebo in Endometrial Cancer | completed | Phase 2 | 146 | Nordic Society of Gynaecological Oncology - Clinical Trials UnitOTHER | 7 | Jul 29, 2025 | clinicaltrials |
| NCT05011058 | An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas(NAVAL-1) | terminated | Phase 2 | 102 | Viracta Therapeutics, Inc.INDUSTRY | 14 | Jul 28, 2025 | clinicaltrials |
| NCT03421288 | Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness(DANTE) | active not recruiting | Phase 2 | 677 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 2 | Jul 25, 2025 | clinicaltrials |
| NCT04579679 | Open-Label Surufatinib in European Patients With NET | terminated | Phase 2 | 78 | HutchmedINDUSTRY | 7 | Jul 25, 2025 | clinicaltrials |
| NCT05182385 | Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) | active not recruiting | Phase 1 / Phase 2 | 30 | Goethe UniversityOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT06940388 | Total Neoadjuvant Treatment With or Without Tislelizumab for Locally Advanced Rectal Cancer.(TOTAL) | recruiting | Phase 2 | 134 | brenner baruchOTHER | 2 | Jul 24, 2025 | clinicaltrials |
| NCT05101629 | Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based Therapy | completed | Phase 2 | 32 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT02763319 | A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)(B-MIND) | completed | Phase 2 / Phase 3 | 453 | Incyte CorporationINDUSTRY | 23 | Jul 17, 2025 | clinicaltrials |
| NCT04259450 | Study to Assess AFM24 in Advanced Solid Cancers | terminated | Phase 1 / Phase 2 | 85 | Affimed GmbHINDUSTRY | 5 | Jul 17, 2025 | clinicaltrials |
| NCT03144674 | A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204) | completed | Phase 2 | 110 | Incyte CorporationINDUSTRY | 12 | Jul 11, 2025 | clinicaltrials |
| NCT02234050 | Trabectedin for Recurrent Grade II/III Meningioma | completed | Phase 2 | 90 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 10 | Jul 10, 2025 | clinicaltrials |
| NCT02611024 | Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors | completed | Phase 1 / Phase 2 | 316 | PharmaMarINDUSTRY | 6 | Jul 9, 2025 | clinicaltrials |
| NCT06926673 | Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3 | completed | Phase 2 | 62 | GlaxoSmithKlineINDUSTRY | 6 | Jul 3, 2025 | clinicaltrials |
| NCT06669117 | FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations | recruiting | Phase 1 / Phase 2 | 140 | Pierre Fabre MedicamentINDUSTRY | 9 | Jul 2, 2025 | clinicaltrials |
| NCT05330429 | Study of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)(ELEVATE CRC) | terminated | Phase 2 | 77 | Gilead SciencesINDUSTRY | 10 | Jul 1, 2025 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials